Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Electronic Journal of Statistics
|
June 11, 2026
Variable selection for single-index varying-coefficients models with applications to synergistic G × E interactions
Shunjie Guan, Mingtao Zhao, Yuehua Cui
Human Gene Therapy
|
December 4, 2021
Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States
Arpana Khatri, Rajani Shelke, Shunjie Guan, et al.
The Journal of Rheumatology
|
July 15, 2023
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman, Craig Hyde, Shunjie Guan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 30, 2025
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
Wuyan Zhang, Steven G Terra, Edward Alan Weinstein, et al.
Ebiomedicine
|
July 1, 2025
Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19
Mary Lynn Baniecki, Shunjie Guan, Devendra K Rai, et al.
Pediatrics
|
June 24, 2026
Nirmatrelvir/Ritonavir for the Treatment of COVID-19 in Children Aged 6 Years and Older
Jacqueline Gerhart, Heidi Leister-Tebbe, Phylinda L S Chan, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Edward Weinstein, Roger Paredes, Annie Gardner, et al.
Science Advances
|
July 24, 2024
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Yuao Zhu, Irina Yurgelonis, Stephen Noell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Electronic Journal of Statistics
|
June 11, 2026
Variable selection for single-index varying-coefficients models with applications to synergistic G × E interactions
Shunjie Guan, Mingtao Zhao, Yuehua Cui
Human Gene Therapy
|
December 4, 2021
Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States
Arpana Khatri, Rajani Shelke, Shunjie Guan, et al.
The Journal of Rheumatology
|
July 15, 2023
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman, Craig Hyde, Shunjie Guan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 30, 2025
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
Wuyan Zhang, Steven G Terra, Edward Alan Weinstein, et al.
Ebiomedicine
|
July 1, 2025
Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19
Mary Lynn Baniecki, Shunjie Guan, Devendra K Rai, et al.
Pediatrics
|
June 24, 2026
Nirmatrelvir/Ritonavir for the Treatment of COVID-19 in Children Aged 6 Years and Older
Jacqueline Gerhart, Heidi Leister-Tebbe, Phylinda L S Chan, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Edward Weinstein, Roger Paredes, Annie Gardner, et al.
Science Advances
|
July 24, 2024
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Yuao Zhu, Irina Yurgelonis, Stephen Noell, et al.
Page
of 1